GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACON) » Definitions » Net Current Asset Value

Aclarion (Aclarion) Net Current Asset Value : $0.18 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Aclarion Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Aclarion's net current asset value per share for the quarter that ended in Mar. 2024 was $0.18.

The historical rank and industry rank for Aclarion's Net Current Asset Value or its related term are showing as below:

ACON' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.68   Med: 2.97   Max: 4.5
Current: 1.68

During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of Aclarion was 4.50. The lowest was 1.68. And the median was 2.97.

ACON's Price-to-Net-Current-Asset-Value is ranked better than
85.94% of 249 companies
in the Healthcare Providers & Services industry
Industry Median: 6.33 vs ACON: 1.68

Aclarion Net Current Asset Value Historical Data

The historical data trend for Aclarion's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclarion Net Current Asset Value Chart

Aclarion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
-6.49 -18.44 -15.35 2.06 -2.30

Aclarion Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -2.33 -3.90 -2.30 0.18

Competitive Comparison of Aclarion's Net Current Asset Value

For the Health Information Services subindustry, Aclarion's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclarion's Price-to-Net-Current-Asset-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Aclarion's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Aclarion's Price-to-Net-Current-Asset-Value falls into.



Aclarion Net Current Asset Value Calculation

Aclarion's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.289-3.188-0-0)/0.82539
=-2.30

Aclarion's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2024 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(2.538-1.222-0-0)/7.1535
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aclarion  (NAS:ACON) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Aclarion Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Aclarion's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclarion (Aclarion) Business Description

Traded in Other Exchanges
N/A
Address
8181 Arista Place, Suite 300, Broomfield, CO, USA, 80021
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
Executives
John Paul Lorbiecki officer: Chief Financial Officer 238 CHEYENNE DRIVE, LAFAYETTE CO 80026
Brent Ness director, officer: Chief Executive Officer 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Ryan Bond officer: Chief Strategy Officer 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Stephen Deitsch director 1600 BROADWAY, SUITE 700, DENVER CO 80202
William Wesemann director 130 MONTALVO ROAD, REDWOOD CITY CA 94062
Jeffrey John Thramann director, officer: Executive Chairman 8580 STRAWBERRY LANE, NIWOT CO 80503
Michael W Dirks 10 percent owner 811 EAST 30TH AVE, HUTCHINSON KS 67502
Nuvasive Inc 10 percent owner 7475 LUSK BLVD, SAN DIEGO CA 92121
Sc Capital 1 Llc 10 percent owner 1 COMPOUND DRIVE, HUTCHINSON KS 67502
Scott Breidbart director 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404
Amanda Mae Sequira director 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
David K Neal director C/O ACLARION, INC., 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404